CR6395A - COMBINATION CHEMOTHERAPY - Google Patents

COMBINATION CHEMOTHERAPY

Info

Publication number
CR6395A
CR6395A CR6395A CR6395A CR6395A CR 6395 A CR6395 A CR 6395A CR 6395 A CR6395 A CR 6395A CR 6395 A CR6395 A CR 6395A CR 6395 A CR6395 A CR 6395A
Authority
CR
Costa Rica
Prior art keywords
combination chemotherapy
combination
fenil
paclitaxel
compound
Prior art date
Application number
CR6395A
Other languages
Spanish (es)
Inventor
Carelton Gowan Richard
Leopold Sebold Judith
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6395A publication Critical patent/CR6395A/en

Links

Abstract

INHIBIDORES MITOTICO TALES COMO EL PACLITAXEL TIENEN ACTIVIDAD ANTITUMORAL MEJORADA UANDO SE USAN EN COMBINACION CON UN INHIBIDOR DE MEK SELECTIVO ESPECIALMENTE UN COMPUESTO FENIL AMINA DE LA FORMULA (I) Y (II).MITOTIC INHIBITORS SUCH AS THE PACLITAXEL HAVE IMPROVED ANTITUMORAL ACTIVITY WHEN USED IN COMBINATION WITH A SPECIFICALLY SELECTIVE MEK INHIBITOR A FORMULA FENIL COMPOUND (I) AND (II).

CR6395A 1998-12-22 2001-06-19 COMBINATION CHEMOTHERAPY CR6395A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
CR6395A true CR6395A (en) 2004-03-09

Family

ID=27733552

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6395A CR6395A (en) 1998-12-22 2001-06-19 COMBINATION CHEMOTHERAPY

Country Status (2)

Country Link
CR (1) CR6395A (en)
ZA (1) ZA200104277B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5651125B2 (en) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド MEK mutations that confer resistance to MEK inhibitors
MX360932B (en) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Braf mutations conferring resistance to braf inhibitors.
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
ZA200104277B (en) 2002-08-26

Similar Documents

Publication Publication Date Title
AP2001002175A0 (en) Combination chemotherapy.
RS50510B (en) FORMULATIONS CONTAINING ECTEINASCIDINE AND DISAHARID
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
ATE516041T1 (en) SYNERGISTIC COMPOSITIONS WITH FK-228
MXPA06000247A (en) Substituted tetrahydro-1h.
HK1057553A1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents forthe inhibition of the cell proliferation.
MX2008016370A (en) Triple activity drilling ship.
ID29076A (en) COMBINATION OF FUNICIDE ACTIVITIES
PT892780E (en) M-AMIDINE PHENYL ANALOGS AS FACTOR XA INHIBITORS
HRP20080499T3 (en) Tetrahydropyridothiophenes
BR9906070A (en) Substituted benzamides
JO2212B1 (en) Tri-aryl-subustituted -ethane pde4 inhibitors
GT199900173A (en) ISOSORBIDA MONONITRATE DERIVATIVES AND THEIR EMPLOYMENT AS VASODILATATING AGENTS WITH DECREASED TOLERANCE.
DK1023268T3 (en) Isoquinolines as urokinase inhibitors.
ATE397861T1 (en) SYNERGISTIC COMPOSITIONS
AR048826A1 (en) ANTITRANSPIRING COMPOSITIONS
ATE404602T1 (en) AQUEOUS POLYURETHANE PREPARATIONS
CR6395A (en) COMBINATION CHEMOTHERAPY
BR0116205A (en) Antimicrobial 2-pyridones, their compositions and uses
NO20052680D0 (en) Improvement agent containing fuel.
AR026901A1 (en) PEPTIDES WITH N-RENT THAT HAVE ANTIANGIOGEN ACTIVITY
MX9304152A (en) ENZYME INHIBITORS.
ES2135535T3 (en) TIAZOLOTRIAZOL AND TIAZOLODIAZOL DERIVATIVES WITH FUNGICIDE ACTIVITY.
DE60011300D1 (en) INHIBITORS OF TRYPTASE
ITRM20020108V0 (en) PLAY AND WORK STATION.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)